Name: Latest research reports of Glenmark Pharmaceuticals Ltd. authored by Deven Choksey and published by - Trendlyne research reports.
Item: Glenmark Pharmaceuticals Ltd.
Rating: 5
Author: Deven Choksey

Sansera Engineering Ltd.

11 Jul 2025, 12:00AM

1354.70

-2.82%

BP Equities Sansera Engineering Ltd. Management Meet Note 11th July 2025

Not Rated: Sansera Engineering Ltd.

BP Wealth

Strategic shift in vertical to unlock higher potential We recently met the management of Sansera Engineering Limited (SEL) with a view to gain greater insights of its business. SEL is a technology driven manufacturer of complex and critical highprecision iron and aluminium components for automotive and non- automotive sectors. It is the largest supplier of Connecting Rods, Rocker Arms and Gear Shifter Forks for the 2W segment and the largest supplier of Connecting Rods and Rocker arms for LMVs in India. Furthermore, the company is among the top ten suppliers of Connecting Rod across international markets. With a strong presence in the high precision IC engine components, it has been able to extend its design and engineering capabilities to cater to fast-growing areas like EV, Defence, Aerospace, etc. Sansera has 17 integrated manufacturing facilities (16 in India and 1 in Sweden) and has evolved organically by supplying premium quality components to Auto ICE, Tech Agnostic, xEV, and Non-Auto OEMs in the domestic and global markets. Following are the key takeaways from the interaction: Multi-vertical evolution unlocks sustainable and robust growth pathways SEL is undergoing a strategic transformation aimed at reducing its dependence on the traditional...

Sansera Engineering Ltd. is trading above its 200 day SMA of 1352.5

Glenmark Pharmaceuticals Ltd.

11 Jul 2025, 12:00AM

2181.10

14.55%

Stock Flash

Buy: Glenmark Pharmaceuticals Ltd.

Deven Choksey

Ichnos Glenmark Innovation (IGI), a wholly-owned subsidiary of Glenmark
Pharmaceuticals, has entered into an exclusive global licensing agreement
with AbbVie for the development and commercialization of IGI’s lead
oncology asset, ISB 2001. This first-in-class CD38×BCMA×CD3 trispecific
antibody is currently in Phase 1 clinical trials for relapsed/refractory multiple
myeloma (R/R MM).

Deven Choksey released a Buy report for Glenmark Pharmaceuticals Ltd. with a price target of 1650.0 on 11 Jul, 2025.

Nifty 50

11 Jul 2025, 12:00AM

25149.85

-0.81%

Daily Derivative Report

Nifty 50

SBI Securities

Retail Research

Nifty 50 is trading above all available SMAs

Bank Nifty

11 Jul 2025, 12:00AM

56754.70

-0.35%

Daily Market Mirror

Bank Nifty

SBI Securities

End of Day Summary

SBI Securities released a Daily Note report for Bank Nifty on 11 Jul, 2025.

Tata Elxsi Ltd.

11 Jul 2025, 12:00AM

6066.00

-1.16%

Weak print; deal ramp-ups from Q2FY26

Sell: Tata Elxsi Ltd.

Target

ICICI Securities Limited

TATA Elxsi (TELX) reported a disappointing print vs I-Sec’s already muted estimates. Q1FY26 marks the fourth straight quarter of muted revenue performance.

Tata Elxsi Ltd. is trading above its 100 day SMA of 5865.5

Tata Consultancy Services Ltd.

11 Jul 2025, 12:00AM

3266.00

-3.43%

Tata Consultancy Services Ltd Q1FY26

Buy: Tata Consultancy Services ...

Deven Choksey

We have revised our FY26E/FY27E EPS estimate by -1.7%/-3.6% respectively, led by lower revenue conversion on the back of reduced demand. We value TCS at 25.0x Jun’27 EPS (~10-year avg NTM P/E), implying a target price of INR 4,067.

Deven Choksey released a Buy report for Tata Consultancy Services Ltd. with a price target of 4067.0 on 11 Jul, 2025.

Construction Materials

SECTOR | 10 Jul 2025, 07:02PM

BP Equities Cement Monthly Update June 2025

Construction Materials

BP Wealth

BP Wealth released a Sector Update report for Construction Materials on 10 Jul, 2025.

Anthem Biosciences Ltd.

10 Jul 2025

Anthem Biosciences Ltd IPO Note

IPO Subscribe: Anthem Biosciences Ltd.

SBI Securities

Anthem Biosciences Ltd. is a fast-growing innovation-led CRDMO (Contract Research Development and Manufacturing Organization) in India, offering endto-end services across drug discovery, development and manufacturing for both New Chemical Entity (NCE) and New Biological Entity (NBE). Serving global biotech and pharma companies, the company reached Rs 1,000 cr in revenue...